
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of 

 disease in patients enrolled in four trials. 

Ophthalmology

Conference

Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Modern Retina® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the retinal and ophthalmic communities.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease. 

Safety and efficacy of KPI-121 0.25% for DED treatment